162 related articles for article (PubMed ID: 38573707)
1. The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.
Martin MV; Aguilar-Rosas S; Franke K; Pieterse M; Langelaar JV; Schreurs R; Bijlsma MF; Besselink MG; Koster J; Timens W; Khasraw M; Ashley DM; Keir ST; Ottensmeier CH; King EV; Verheij J; Waasdorp C; Valk PJM; Engels SAG; Oostenbach E; van Dinter JT; Hofman DA; Mok JY; van Esch WJE; Wilmink H; Monkhorst K; Verheul HMW; Poel D; Hiltermann TJN; Kempen LCLTV; Groen HJM; Aerts JGJV; Heesch SV; Löwenberg B; Plasterk R; Kloosterman WP
Cancer Immunol Res; 2024 Jun; 12(6):759-778. PubMed ID: 38573707
[TBL] [Abstract][Full Text] [Related]
2. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients.
Koster J; Plasterk RHA
Sci Rep; 2019 Apr; 9(1):6577. PubMed ID: 31036835
[TBL] [Abstract][Full Text] [Related]
3. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
4. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
5. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
Yang W; Lee KW; Srivastava RM; Kuo F; Krishna C; Chowell D; Makarov V; Hoen D; Dalin MG; Wexler L; Ghossein R; Katabi N; Nadeem Z; Cohen MA; Tian SK; Robine N; Arora K; Geiger H; Agius P; Bouvier N; Huberman K; Vanness K; Havel JJ; Sims JS; Samstein RM; Mandal R; Tepe J; Ganly I; Ho AL; Riaz N; Wong RJ; Shukla N; Chan TA; Morris LGT
Nat Med; 2019 May; 25(5):767-775. PubMed ID: 31011208
[TBL] [Abstract][Full Text] [Related]
7. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
8. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
9. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
10. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
11. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
12. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
[TBL] [Abstract][Full Text] [Related]
14. Determinants for Neoantigen Identification.
Garcia-Garijo A; Fajardo CA; Gros A
Front Immunol; 2019; 10():1392. PubMed ID: 31293573
[TBL] [Abstract][Full Text] [Related]
15. Neoantigens: promising targets for cancer therapy.
Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.
Shi Y; Jing B; Xi R
Genome Biol; 2023 Jul; 24(1):169. PubMed ID: 37461029
[TBL] [Abstract][Full Text] [Related]
17. FusionNeoAntigen: a resource of fusion gene-specific neoantigens.
Kumar H; Luo R; Wen J; Yang C; Zhou X; Kim P
Nucleic Acids Res; 2024 Jan; 52(D1):D1276-D1288. PubMed ID: 37870454
[TBL] [Abstract][Full Text] [Related]
18. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
19. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
